Go Back To Menu
Close
- Mailing Form
-
Medical Report*
-
Go Back To Menu
"Pancreatic cancer" usually refers to pancreatic ductal adenocarcinoma (including its subtypes), accounting for about 85% of all pancreatic tumors. The long-term prognosis of most ductal adenocarcinoma subtypes is generally poor and similar, except mucinous carcinoma, which has a better prognosis, while adenosquamous carcinoma fares worse than other subtypes.
It is rare in people under 45 years old, but the incidence rises sharply after age 45. According to the Global Burden of Disease Study, the peak incidence ages are 65–69 years for men and 75–79 years for women.
The most common complaints of pancreatic cancer patients are pain, jaundice, and weight loss. It is a highly lethal malignancy, ranking 4th among cancer-related deaths in the United States and 2nd among digestive system cancer-related deaths, second only to colorectal cancer.
Pancreatic cancer shows an increasing trend worldwide, with higher incidence in developed Western countries. Some Asian countries, such as Japan and South Korea, also have a relatively high number of patients, while incidence in Southeast Asia is relatively lower. However, due to disparities in medical conditions, a higher proportion of cases are diagnosed at advanced stages, resulting in high mortality.
Globally, pancreatic cancer is the sixth leading cause of cancer death. It is more common in Western and industrialized regions. The regions with the highest reported incidence are high-income North America, high-income Asia-Pacific, Western Europe, and Central Europe, while the lowest incidence rates are seen in South Asia and sub-Saharan Africa (East and Central). In the U.S., more than 67,000 cases of exocrine pancreatic cancer are diagnosed annually, and most are expected to die from the disease.
1. High Concealment
Pancreatic cancer usually has no obvious symptoms in the early stages, and the tumor has often already spread before detection, causing patients to miss the optimal treatment window.
2. High Invasiveness
Pancreatic cancer cells have strong invasive and metastatic abilities, commonly spreading to lymph nodes, the liver, and the peritoneum, making treatment extremely difficult.
3. High Treatment Difficulty
Pancreatic cancer is poorly sensitive to radiotherapy and chemotherapy, traditional treatment effects are limited, surgical resection rates are low, and overall prognosis is poor.
4. Low Survival Rate
Due to late diagnosis and delayed treatment, the overall 5-year survival rate for pancreatic cancer patients is extremely low, making it one of the deadliest cancer types.
Immune reconstruction cell therapy reinfuses immune cells with recognition and attack abilities to activate the body’s anti-tumor immune mechanisms while improving the tumor microenvironment. This therapy can synergize with radiotherapy, chemotherapy, and surgery, delay recurrence and metastasis, and is especially suitable for advanced pancreatic cancer patients, helping to improve survival rates and quality of life. It is an important part of current innovative treatment approaches.
In clinical practice, cancer patients undergoing surgery, radiotherapy, and chemotherapy often face impaired immune function, increased risk of infection, and slow recovery. To better support patients during treatment, improve tolerance, and enhance quality of life, it is necessary to scientifically design phased immune reconstruction plans tailored to different treatment cycles.
● Short-term Plan: Rapidly enhance immunity through immune cell reinfusion to boost the effectiveness of anti-cancer treatment.
● Mid-term Plan: Reduce side effects of traditional treatments, promote physical recovery, and complete standardized treatment courses.
● Long-term Plan: Strengthen overall immunity through immune cell reconstruction, gut immune reconstruction, elemental immune reconstruction, and immune nutrition reconstruction to improve quality of life and extend survival.
1. Surgical Treatment
Surgical resection is an important curative treatment for pancreatic cancer, mainly for early localized lesions. With the development of minimally invasive technology, laparoscopic and robot-assisted surgery are becoming trends, reducing surgical trauma and accelerating recovery.
2. Radiotherapy and Chemotherapy
Radiotherapy and chemotherapy serve as adjuvant treatments to control local lesions and slow tumor progression. New chemotherapeutic drugs and combination regimens continue to emerge, improving outcomes for some advanced patients.
3. Targeted Therapy and Others
Targeted therapy focuses on molecular mechanisms specific to pancreatic cancer, providing personalized treatment plans. Minimally invasive technologies such as radiofrequency ablation and percutaneous tumor ablation are also used in some patients to reduce tumor burden.
4. Minimally Invasive Interventions
Some patients can benefit from interventions such as ablation, percutaneous drainage, and biliary stent placement to relieve bile duct obstruction, bleeding, and other complications caused by tumors. These methods improve quality of life and slow disease progression, especially for inoperable or frail patients.
Pancreatic cancer poses tremendous treatment challenges due to its concealment and aggressiveness, making early diagnosis and comprehensive treatment essential. Experts at United Life International Medical Center emphasize that combining immune reconstruction cell therapy with modern minimally invasive techniques offers hope for improving patient outcomes and quality of life.
